Genetics in Autoimmune Hepatitis

Peter T. Donaldson

doi:10.1055/s-2002-35705

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2002; 22(4): 353-364
DOI: 10.1055/s-2002-35705

Genetics in Autoimmune Hepatitis

Peter T. Donaldson

Lecturer in Molecular Genetics, Centre for Liver Research, School of Clinical Medical Sciences, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Abstract

ABSTRACT

Current hypotheses suggest that autoimmune hepatitis (AIH) is triggered by an environmental factor in a genetically susceptible host. Multiple genes may interact to produce a ``permissive gene pool'' that determines both disease risk and phenotype. Studies of type 1 AIH have focused on the major histocompatibility complex (MHC), mapping susceptibility to the DRB1 region. Three different molecular models have been proposed based on histidine at DRβ13, lysine at DRβ71, and valine at DRβ86. Although the lysine-71 model has been adapted to explain data from several other studies, the DRβ13 and DRβ86 models are exclusive to their founder populations. It is possible that all three models apply and that the different associations reflect the ``molecular footprint'' of the common environmental triggers in the different study populations. Studies outside the MHC have identified the CTLA4 A+49G, G allele as a possible second risk allele. There are many neutral polymorphisms in the genome, and further studies are currently needed to identify other disease alleles in type 1 AIH.

KEYWORDS

Genetic susceptibility - MHC - CTLA4 - permissive gene pool - molecular footprint

Volltext

Referenzen

REFERENCES

1 Dennis C, Gallagher R, Campbell P. Theme issue on the human genome. Nature . 2001; 409 813-958
2 Czaja A J, Donaldson P T. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev . 2000; 174 250-259
3 Cardon L R, Bell J I. Association study designs for complex disease. Nature Reviews . 2001; 2 91-99
4 Becker K G, Simon R M, Bailey-Wilson J E. Clustering of non-major histocompatibility complex susceptibility loci in human autoimmune diseases. Proc Natl Acad Sci USA . 1998; 95 9979-9984
5 Anonymous. Freely associating. Nat Genet . 1999; 22 1-2
6 Risch N J. Searching for genetic determinants in the new millennium. Nature . 2000; 405 847-856
7 Todd J A. Interpretation of results from genetic studies of multifactorial disease. Lancet . 1999; 354(Suppl 1) 15-16
8 Todd J A. Tackling common disease. Nature . 2001; 411 537-539
9 Donaldson P, Agarwal K, Craggs A. HLA and interleukin-1 gene polymorphisms in primary biliary cirrhosis associations with disease progression and disease susceptibility. Gut . 2001; 48 397-402
10 Milner C M, Campbell D R, Trowsdale J. Molecular genetics of the human major histocompatibility complex. In: Warrens A, Lechler R, eds. HLA in Health and Disease New York: Academic Press 2000: 35-50
11 Eren E, Travers P. The structure of the major histocompatibility complex and its molecular interactions. In: Warrens A, Lechler R, eds. HLA in Health and Disease New York: Academic Press 2000: 23-34
12 Baker R J, Warrens A N. The biology of major histocompatibility complex molecules. In: Warrens A, Lechler R, eds. HLA in Health and Disease New York: Academic Press 2000: 51-72
13 Chen A P, Purcell A W, McCluskey J. The biology of major histocompatibility complex molecules. II: Antigen processing and presentation. In: Warrens A, Lechler R, eds. HLA in Health and Disease New York: Academic Press 2000: 73-106
14 Briggs D C, Donaldson P T, Hayes P. A major histocompatibility complex Class III allotype C4B2 associated with primary biliary cirrhosis. Tissue Antigens . 1987; 29 141-145
15 Manns M P, Bremm A, Schneider P M. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology . 1991; 101 1367-1373
16 Fanning G C, Bunce M, Black C M. Polymerase chain reaction haplotyping using &3acute; mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumour necrosis factor and lymphotoxin-α. Tissue Antigens . 1997; 50 23-31
17 Price P, Witt C, Allcock R. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev . 1999; 167 257-274
18 Tilg H, Diehl A M. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med . 2000; 343 1467-1476
19 Groh V, Bahram S, Bauer S. Cell stress regulated human major histocompatibility complex class I gene-regulated in gastrointestinal epithelium. Proc Natl Acad Sci USA . 1996; 93 12445-12450
20 Bauer S, Groh V, Wu J. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science . 1999; 285 727-729
21 Norris S, Doherty D G, McEntee G. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogeneous and include Vα24JαQ and γδ T cell receptor bearing cells. Hum Immunol . 1999; 60 20-31
22 Perez V L, Parijs L V, Biuckians A. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity . 1997; 6 411-417
23 McCoy K D, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol . 1999; 77 1-10
24 Johnson G CL, Esposito L, Barratt B J. Haplotype tagging for the identification of common disease genes. Nat Genet . 2001; 29 233-237
25 Kristiansen O P, Larsen Z M, Pocoit F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity?. Genes and Immunity . 2000; 1 170-184
26 Bidwell J, Keen L, Gallagher G. Cytokine gene polymorphism in human disease: on-line databases. Genes and Immunity . 1999; 1 3-19
27 The International SNP Map Working group. A map of the human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature . 2001; 409 928-933
28 Dinarello C A. Biological basis for interleukin-1 in disease. Blood . 1996; 87 2095-2147
29 Laurincova B. Interleukin-1 family: from genes to human disease. Acta Univ Palacki Olomuc Fac Med . 2000; 143 19-29
30 Bergholdt R, Larsen Z M, Andersen N A. Characterisation of new polymorphisms in the 5'UTR of the human interleukin-1 receptor type 1 (IL1R1) gene: linkage to type 1 diabetes and correlation to IL-1R1 plasma level. Genes and Immunity . 2000; 1 495-500
31 Eskdale J, Keijsers V, Huizinga T. Microsatellites and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes and Immunity . 1999; 1 151-155
32 Mackay I R, Morris P J. Association of autoimmune active hepatitis with HL-A1, 8. Lancet . 1972; ii 793-795
33 Czaja A J, Manns M P, McFarlane I G. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology . 2000; 31 1194-1200
34 Donaldson P T, Manns M P. Immunogenetics of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, et al, eds. Oxford Textbook of Clinical Hepatology Oxford: Oxford University Press 1999: 173-188
35 Oplez G, Votgen A GM, Summerskill W HJ, Schalm S W, Terasaki P I. HLA determinant in chronic active liver disease: a possible relation of HLA-Dw3 to prognosis. Tissue Antigens . 1977; 9 36-40
36 Lepage V, Degos F, Carella M. HLA-Cw7 and HBS Ag negative chronic active hepatitis. Tissue Antigens . 1981; 18 105-107
37 Williams M R, Martin S, Falchuk K R. Increased frequency of HLA-DRw4 in chronic active hepatitis. Vox Sang . 1978; 35 366-369
38 Mackay I R, Tait B D. HLA associations with autoimmune type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology . 1980; 79 95-98
39 Donaldson P T, Doherty D G, Hayllar K M. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology . 1991; 13 701-706
40 Doherty D G, Donaldson P T, Underhill J A. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology . 1994; 19 609-615
41 Strettell M DJ, Donaldson P T, Thompson L J. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology . 1997; 112 2028-2035
42 Strettell M DJ, Thomson L J, Donaldson P T. HLA-C genes and susceptibility to type I autoimmune hepatitis. Hepatology . 1997; 26 1203-1206
43 Cookson S, Constantini P K, Clare M. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology . 1999; 30 851-856
44 Manabe K, Donaldson P T, Underhill J A. HLA A1-B8-DR3-DQ2-DPB1*0401 extended haplotype in autoimmune hepatitis. Hepatology . 1993; 18 1334-1337
45 Ota M, Seki T, Kiyosawa K. A possible association between basic amino acids at position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics . 1992; 36 49-55
46 Fainboim L, Marcos Y, Pando M. Chronic active autoimmune hepatitis in children: strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol . 1994; 41 146-150
47 Vazquez-Garcia M N, Alaez C, Olivo A. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol . 1998; 28 985-990
48 Pando M, Lariba J, Fernadez G C. Paediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology . 1999; 30 1374-1380
49 Stern L J, Brown J H, Jardetsky T S. Crystal structure of human class II MHC protein HLA-DR1 complexed with influenza virus peptide. Nature . 1994; 368 215-221
50 Brown J H, Jardetzky T S, Gorga J C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature . 1993; 304 33-39
51 Nepom G T. A unified hypothesis for the complex genetics of HLA associations with IDDM. Diabetes . 1990; 39 1153-1157
52 Sheehy M J. HLA and insulin-dependent diabetes: a protective perspective. Diabetes . 1992; 41 123-129
53 Busch R, Hill C M, Hayball J D. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding. J Immunol . 1998; 113 244-251
54 Doherty D G, Penzotti J E, Koelle D M. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol . 1998; 161 3527-3535
55 Nepom G T. HLA and rheumatoid arthritis. In: Warrens A, Lechler R, eds. HLA in Health and Disease New York: Academic Press 2000: 181-186
56 Donaldson P T, Norris S. Immunogenetics in PSC. Ballieres Clin Gastroenterol . 2001; 15 611-627
57 Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Ballieres Clin Gastroenterol . 2001; 15 681-690
58 Fainboim L, Velasco M CC, Marcos C Y. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for paediatric autoimmune hepatitis. Hepatology . 2001; 33 1512-1517
59 Tapia-Conyer R, Santos J I, Cavalcanti A M. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg . 1999; 61 825-829
60 Czaja A J, Carpenter H A, Santrach P J. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology . 1993; 105 1502-1507
61 Czaja A J, Strettell M DJ, Thomson L J. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology . 1997; 25 317-323
62 Seki T, Ota M, Furuta S. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology . 1992; 103 1041-1047
63 Czaja A J, Rakela J, Hay J E. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology . 1990; 98 1587-1593
64 Sanchez-Urdazpal L, Czaja A J, van Hoek B. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology . 1992; 15 215-221
65 Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 AIH. Am J Gastroenterol . 2002; 97 413-419
66 Czaja A J, Carpenter H A, Santrach P J. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology . 1993; 18 816-822
67 Doherty D G, Underhill J A, Donaldson P T. Polymorphism in the human complement C4 genes and susceptibility to autoimmune hepatitis. Autoimmunity . 1994; 18 243-249
68 Cookson S, Constantini P K, Clare M. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology . 1999; 30 851-856
69 Bittencourt L P, Palacios S A, Cancado E LR. Autoimmune hepatitis in Brazilian patients is not linked to tumour necrosis factor a polymorphisms at position -308. J Hepatol . 2001; 35 24-28
70 Norris S, Kondeatis E, Collins R. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology . 2001; 120 1475-1482
71 Stephens H AF. MICA and MICB genes: can the enigma of their polymorphism be resolved. Trends in Immunology . 2001; 22 378-385
72 Wiencke K, Spurkland A, Schrumpf E, Boberg K M. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology . 2001; 34 625-630
73 Manabe K, Hibberd M L, Donaldson P T. T-cell receptor constant germline gene polymorphisms and susceptibility to autoimmune hepatitis. Gastroenterology . 1994; 106 1321-1325
74 Whittingham S, Mathews J D, Schanfield M S. Interaction of HLA and Gm in autoimmune chronic active hepatitis. Clin Exp Immunol . 1981; 43 80-86
75 Yanagawa T, Hidaka Y, Guimaraes V. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metabol . 1995; 80 41-45
76 Kouki T, Sawai Y, Gardine C A. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol . 2000; 165 6606-6611
77 Van der Auwera J B, Vandewalle C L, Schuit F C. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. Clin Exp Immunol . 1997; 110 98-103
78 Agarwal K, Jones D EJ, Daly A K. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol . 2000; 32 538-541
79 Agarwal K, Czaja A J, Jones D EJ. CTLA-4 polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology . 2000; 31 49-53
80 Czaja A J, Cookson S, Constantini P K. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology . 1999; 117 645-652
81 Donaldson P T, Norris S, Constantini P K, Harrison P, Williams R. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: no associations with disease susceptibility/resistance. J Hepatol . 2000; 32 882-886
82 Zappala F, Grove J, Watt F E. No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol . 1998; 28 820-823
83 Hampe J, Cuthbert A, Croucher P JP. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet . 2001; 357 1925-1928
84 Hugot J-P, Chamaillard M, Zouali H. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature . 2001; 411 599-603
85 Ogura Y, Bonen D K, Inohara N. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature . 2001; 411 603-606
86 Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity . 2001; 15 5-14
87 Rust C, Gores G J. Apoptosis and liver disease. Am J Med . 2000; 108 567-574